Literature DB >> 7729900

Variation in the structure of glucuronoxylomannan in isolates from patients with recurrent cryptococcal meningitis.

R Cherniak1, L C Morris, T Belay, E D Spitzer, A Casadevall.   

Abstract

Capsular glucuronoxylomannans (GXM) of Cryptococcus neoformans var. neoformans isolates from patients with recurrent cryptococcal meningitis were analyzed by 1H nuclear magnetic resonance spectroscopy and for reactivity with factor sera (Iatron, Tokyo, Japan). For each patient the initial and relapse isolates had previously been shown to be indistinguishable by DNA restriction fragment length polymorphism analysis. For patients J11 and J22 the GXM of the initial and relapse isolates were identical. For patients SB4 and SB6 the GXM of the initial and relapse isolates differed in structure and reactivity with factor sera. In patient SB4 the initial isolate had a serotype A/D structure, and the first relapse isolate had a serotype A structure. The second relapse isolate was a mixture of structures composed of serotype D components, glucuronomannan (GM), and a minor serotype A component. Analysis of the initial isolate from patient SB6 showed a structure composed mainly of serotype D, GM, and minor serotype A components and components not assigned to a particular serotype (N). The relapse isolate had the same composition as the initial isolate except for an increase in the serotype A component. This increase in the serotype A component of the relapse isolate resulted in a change in the serological specificity from serotype D to serotype A/D. The initial isolate from patient J9 had serotype D and GM structures. The first two relapse isolates had serotype D, N, and GM structures and a minor serotype A component. The third relapse isolate had mainly a serotype D structure. All the J9 isolates reacted only with serotype D-specific factor serum. These results indicate that some isolates obtained from patients with recurrent C. neoformans infections have undergone a change in GXM structure during the course of infection. The modification of GXM structure observed in some relapse isolates is reflected in changed serological properties. The results may have important implications for the design of vaccines and antibody-based therapeutic strategies against C. neoformans.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7729900      PMCID: PMC173241          DOI: 10.1128/iai.63.5.1899-1905.1995

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  42 in total

Review 1.  Role of the capsule in phagocytosis of Cryptococcus neoformans.

Authors:  T R Kozel; G S Pfrommer; A S Guerlain; B A Highison; G J Highison
Journal:  Rev Infect Dis       Date:  1988 Jul-Aug

2.  A new genus, filobasidiella, the perfect state of Cryptococcus neoformans.

Authors:  K J Kwon-Chung
Journal:  Mycologia       Date:  1975 Nov-Dec       Impact factor: 2.696

3.  Recombinational mapping of capsule mutations in Cryptococcus neoformans.

Authors:  C N Still; E S Jacobson
Journal:  J Bacteriol       Date:  1983-10       Impact factor: 3.490

4.  Epidemiologic differences between the two varieties of Cryptococcus neoformans.

Authors:  K J Kwon-Chung; J E Bennett
Journal:  Am J Epidemiol       Date:  1984-07       Impact factor: 4.897

Review 5.  Oxygen metabolism and the toxic properties of phagocytes.

Authors:  S J Klebanoff
Journal:  Ann Intern Med       Date:  1980-09       Impact factor: 25.391

6.  Protection of mice against experimental cryptococcosis by anti-Cryptococcus neoformans monoclonal antibody.

Authors:  F Dromer; J Charreire; A Contrepois; C Carbon; P Yeni
Journal:  Infect Immun       Date:  1987-03       Impact factor: 3.441

7.  Immune response to Cryptococcus neoformans soluble polysaccharide: immunological unresponsiveness.

Authors:  T R Kozel; W F Gulley; J Cazin
Journal:  Infect Immun       Date:  1977-12       Impact factor: 3.441

8.  Cryptococcus neoformans. I. Nonencapsulated mutants.

Authors:  G S Bulmer; M D Sans; C M Gunn
Journal:  J Bacteriol       Date:  1967-11       Impact factor: 3.490

9.  Immunological unresponsiveness induced by cryptococcal capsular polysaccharide assayed by the hemolytic plaque technique.

Authors:  J W Murphy; G C Cozad
Journal:  Infect Immun       Date:  1972-06       Impact factor: 3.441

Review 10.  Capsular polysaccharides of Cryptococcus neoformans.

Authors:  A K Bhattacharjee; J E Bennett; C P Glaudemans
Journal:  Rev Infect Dis       Date:  1984 Sep-Oct
View more
  44 in total

Review 1.  A yeast under cover: the capsule of Cryptococcus neoformans.

Authors:  Indrani Bose; Amy J Reese; Jeramia J Ory; Guilhem Janbon; Tamara L Doering
Journal:  Eukaryot Cell       Date:  2003-08

2.  Immunoreactivity of cryptococcal antigen is not stable under prolonged incubations in human serum.

Authors:  Diane C McFadden; Oscar Zaragoza; Arturo Casadevall
Journal:  J Clin Microbiol       Date:  2004-06       Impact factor: 5.948

Review 3.  Role of phagocytosis in the virulence of Cryptococcus neoformans.

Authors:  Maurizio Del Poeta
Journal:  Eukaryot Cell       Date:  2004-10

Review 4.  Phenotypic switching and its implications for the pathogenesis of Cryptococcus neoformans.

Authors:  Neena Jain; Abraham Guerrero; Bettina C Fries
Journal:  FEMS Yeast Res       Date:  2006-06       Impact factor: 2.796

5.  Effects of antifungal interventions on the outcome of experimental infections with phenotypic switch variants of Cryptococcus neoformans.

Authors:  Bettina C Fries; Emily Cook; Xiabo Wang; Arturo Casadevall
Journal:  Antimicrob Agents Chemother       Date:  2005-01       Impact factor: 5.191

6.  Size Matters: Measurement of Capsule Diameter in Cryptococcus neoformans.

Authors:  Tiffany Guess; Hoyin Lai; Serenah E Smith; Linda Sircy; Kirsten Cunningham; David E Nelson; Erin E McClelland
Journal:  J Vis Exp       Date:  2018-02-27       Impact factor: 1.355

7.  Cryptococcus neoformans var. grubii: separate varietal status for Cryptococcus neoformans serotype A isolates.

Authors:  S P Franzot; I F Salkin; A Casadevall
Journal:  J Clin Microbiol       Date:  1999-03       Impact factor: 5.948

8.  Variable efficacy of passive antibody administration against diverse Cryptococcus neoformans strains.

Authors:  J Mukherjee; M D Scharff; A Casadevall
Journal:  Infect Immun       Date:  1995-09       Impact factor: 3.441

9.  Characterization of a murine monoclonal antibody to Cryptococcus neoformans polysaccharide that is a candidate for human therapeutic studies.

Authors:  A Casadevall; W Cleare; M Feldmesser; A Glatman-Freedman; D L Goldman; T R Kozel; N Lendvai; J Mukherjee; L A Pirofski; J Rivera; A L Rosas; M D Scharff; P Valadon; K Westin; Z Zhong
Journal:  Antimicrob Agents Chemother       Date:  1998-06       Impact factor: 5.191

10.  Antibody action after phagocytosis promotes Cryptococcus neoformans and Cryptococcus gattii macrophage exocytosis with biofilm-like microcolony formation.

Authors:  Mauricio Alvarez; Carolyn Saylor; Arturo Casadevall
Journal:  Cell Microbiol       Date:  2008-04-01       Impact factor: 3.715

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.